BR112022019660A2 - Composições e métodos para tratamento de câncer - Google Patents

Composições e métodos para tratamento de câncer

Info

Publication number
BR112022019660A2
BR112022019660A2 BR112022019660A BR112022019660A BR112022019660A2 BR 112022019660 A2 BR112022019660 A2 BR 112022019660A2 BR 112022019660 A BR112022019660 A BR 112022019660A BR 112022019660 A BR112022019660 A BR 112022019660A BR 112022019660 A2 BR112022019660 A2 BR 112022019660A2
Authority
BR
Brazil
Prior art keywords
methods
compositions
cancer treatment
cancer
treatment
Prior art date
Application number
BR112022019660A
Other languages
English (en)
Inventor
Philipson Richard
Yla-Herttuala Seppo
Original Assignee
Trizell Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trizell Ltd filed Critical Trizell Ltd
Publication of BR112022019660A2 publication Critical patent/BR112022019660A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Surgery (AREA)

Abstract

COMPOSIÇÕES E MÉTODOS PARA TRATAMENTO DE CÂNCER. A presente invenção inclui composições e métodos para o tratamento contra o câncer, como câncer de bexiga.
BR112022019660A 2020-03-30 2021-03-30 Composições e métodos para tratamento de câncer BR112022019660A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063002168P 2020-03-30 2020-03-30
PCT/IB2021/000206 WO2021198777A1 (en) 2020-03-30 2021-03-30 Compositions and methods for treating cancer

Publications (1)

Publication Number Publication Date
BR112022019660A2 true BR112022019660A2 (pt) 2022-11-29

Family

ID=75787139

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022019660A BR112022019660A2 (pt) 2020-03-30 2021-03-30 Composições e métodos para tratamento de câncer

Country Status (11)

Country Link
US (1) US20230226154A1 (pt)
EP (1) EP4125998A1 (pt)
JP (1) JP2023519709A (pt)
KR (1) KR20230012471A (pt)
CN (1) CN115666618A (pt)
AU (1) AU2021250709A1 (pt)
BR (1) BR112022019660A2 (pt)
CA (1) CA3169487A1 (pt)
IL (1) IL296845A (pt)
TW (1) TW202203962A (pt)
WO (1) WO2021198777A1 (pt)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6835557B1 (en) 1980-01-08 2004-12-28 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing human interferon-like polypeptides
US4414150A (en) 1980-11-10 1983-11-08 Genentech, Inc. Hybrid human leukocyte interferons
AU561343B2 (en) 1981-10-19 1987-05-07 Genentech Inc. Human immune interferon by recombinant dna
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4855238A (en) 1983-12-16 1989-08-08 Genentech, Inc. Recombinant gamma interferons having enhanced stability and methods therefor
DE3410439A1 (de) 1984-03-22 1985-09-26 Hoechst Ag, 6230 Frankfurt Verfahren zur herstellung von 6-methyl-3,4-dihydro-1,2,3-oxathiazin-4-on-2,2-dioxid und dessen nichttoxischen salzen sowie der dabei als zwischenprodukt(e) auftretenden acetoacetamind-n-sulfonsaeure(salze)
US6210939B1 (en) 1993-10-25 2001-04-03 Canji, Inc. Recombinant adenoviral vector and methods of use
ES2125696T3 (es) 1996-11-27 1999-03-01 Pfleger R Chem Fab Utilizacion del cloruro de tropsio para la produccion de una preparacion farmaceutica para el tratamiento de disfunciones vesicales.
EP1214039A2 (en) 1999-09-09 2002-06-19 Androsolutions, Inc. Methods and compositions for preventing and treating urinary tract disorders
US8481518B2 (en) 2003-01-16 2013-07-09 University Of Rochester Quaternary antimuscarinic compounds for the treatment of bladder diseases
WO2005058368A1 (en) * 2003-12-10 2005-06-30 Canji, Inc. Methods and compositions for treatment of interferon-resistant tumors
AU2008266951B2 (en) 2007-06-18 2013-12-12 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor PD-1
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
WO2017142818A1 (en) * 2016-02-15 2017-08-24 Fkd Therapies Limited, Improved interferon therapy
WO2019118389A1 (en) * 2017-12-12 2019-06-20 Trizell Limited Cdkn2a companion diagnostic for bladder cancer interferon therapy

Also Published As

Publication number Publication date
JP2023519709A (ja) 2023-05-12
EP4125998A1 (en) 2023-02-08
CN115666618A (zh) 2023-01-31
TW202203962A (zh) 2022-02-01
CA3169487A1 (en) 2021-10-07
KR20230012471A (ko) 2023-01-26
WO2021198777A1 (en) 2021-10-07
AU2021250709A1 (en) 2022-10-13
IL296845A (en) 2022-11-01
US20230226154A1 (en) 2023-07-20

Similar Documents

Publication Publication Date Title
CL2020002914A1 (es) Métodos y composiciones para tratar el cáncer
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
MX2019007030A (es) Composiciones y metodos para el tratamiento del cancer.
CL2019002368A1 (es) Composiciones y métodos para el tratamiento de cáncer.
CL2023003068A1 (es) Compuestos, composiciones y métodos para el tratamiento de trastornos
BR112018067330A2 (pt) método para o tratamento de paciente com carga tumoral
WO2018136617A3 (en) Bacteria for treating cancer
CO2021006672A2 (es) Moduladores de nlrp3
BR112019011199A2 (pt) método para tratar um indivíduo que tem um câncer de próstata e kits
BR112021022784A2 (pt) Composições e métodos para tratamento do câncer
CO2022000481A2 (es) Inhibidores de enzimas
CL2020000085A1 (es) Moduladores de nlrp3.
PH12017501879A1 (en) Methods for treating cancer
CL2019002427A1 (es) Inhibición de smarca2 para el tratamiento de cáncer.
EA201991818A1 (ru) Лечение рака
MX2021000847A (es) Procedimientos para el tratamiento del cancer con el inhibidor de pi3k, gdc 0077.
BR112023005160A2 (pt) Terapia de combinação para o tratamento de câncer
MX2020006297A (es) Variantes de cd19.
PH12018502318A1 (en) Compositions and methods for treatment of inflammation of infection of the eye
AR119681A1 (es) Métodos de tratamiento del cáncer de mama con tucatinib
BR112017007916A2 (pt) compostos sarms para tratamento de distúrbios urológicos
EA202092824A1 (ru) Комбинированная терапия
CL2023003090A1 (es) Combinaciones de composiciones terapéuticas y usos para tratar cánceres
ECSP23056223A (es) Quinolinas y azaquinolinas como inhibidores de cd38
BR112022019660A2 (pt) Composições e métodos para tratamento de câncer